NCT05104905
A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma
Phase: Phase 1/2
Role: Lead Sponsor
Start: Oct 7, 2021
Completion: Jan 28, 2022